Karyopharm Therapeutics Stock Today
| KPTI Stock | USD 1.16 0.06 4.92% |
Performance9 of 100
| Odds Of DistressOver 74
|
Karyopharm Therapeutics is trading at 1.16 as of the 16th of April 2024. This is a -4.92 percent decrease since the beginning of the trading day. The stock's open price was 1.22. Karyopharm Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Karyopharm Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of April 2022 and ending today, the 16th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of November 2013 | Category Healthcare | Classification Health Care |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts. The company has 115.07 M outstanding shares of which 22.95 M shares are now shorted by private and institutional investors with about 17.36 trading days to cover. More on Karyopharm Therapeutics
Moving together with Karyopharm Stock
| 0.66 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.66 | MRK | Merck Company Report 25th of April 2024 | PairCorr |
Moving against Karyopharm Stock
| 0.64 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
| 0.64 | AMGN | Amgen Inc Financial Report 25th of April 2024 | PairCorr |
| 0.62 | BIIB | Biogen Inc Financial Report 23rd of April 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 2nd of May 2024
Karyopharm Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Karyopharm Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Karyopharm Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO President | Richard MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, NASDAQ Composite Total, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Karyopharm Therapeutics report their recommendations after researching Karyopharm Therapeutics' financial statements, talking to executives and customers, or listening in on Karyopharm Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Karyopharm Therapeutics. The Karyopharm consensus assessment is calculated by taking the average forecast from all of the analysts covering Karyopharm Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Karyopharm Therapeutics' liquidity, profitability, solvency, and operating efficiency, Karyopharm Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Karyopharm Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Karyopharm Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Karyopharm Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Karyopharm Therapeutics' financial leverage. It provides some insight into what part of Karyopharm Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Karyopharm Therapeutics (KPTI) is traded on NASDAQ Exchange in USA. It is located in 85 Wells Avenue, Newton, MA, United States, 02459-3298 and employs 325 people. Karyopharm Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 140.76 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Karyopharm Therapeutics's market, we take the total number of its shares issued and multiply it by Karyopharm Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Karyopharm Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 115.07 M outstanding shares of which 22.95 M shares are now shorted by private and institutional investors with about 17.36 trading days to cover.
Karyopharm Therapeutics currently holds about 170.85 M in cash with (92.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.14, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Karyopharm Therapeutics Probability Of Bankruptcy
Ownership AllocationKaryopharm Therapeutics maintains a total of 115.07 Million outstanding shares. Over half of Karyopharm Therapeutics' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Karyopharm Therapeutics. Please watch out for any change in the institutional holdings of Karyopharm Therapeutics as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Karyopharm Ownership Details
Karyopharm Stock Price Odds Analysis
Coming from a normal probability distribution, the odds of Karyopharm Therapeutics jumping above the current price in 90 days from now is about 59.13%. The Karyopharm Therapeutics probability density function shows the probability of Karyopharm Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 3.4485. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Karyopharm Therapeutics will likely underperform. Additionally, karyopharm Therapeutics has an alpha of 0.6503, implying that it can generate a 0.65 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Karyopharm Therapeutics to move above the current price in 90 days from now is about 59.13 (This Karyopharm Therapeutics probability density function shows the probability of Karyopharm Stock to fall within a particular range of prices over 90 days) .
Karyopharm Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Karyopharm Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Karyopharm Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Karyopharm Therapeutics' value.| Instituion | Recorded On | Shares | |
| Marshall Wace Asset Management Ltd | 2023-12-31 | 1.9 M | |
| Bnp Paribas Arbitrage, Sa | 2023-12-31 | 1.8 M | |
| Adage Capital Partners Gp Llc | 2023-12-31 | 1.7 M | |
| Millennium Management Llc | 2023-12-31 | 1.5 M | |
| Cam Group Holding A/s | 2023-12-31 | 1.5 M | |
| Deutsche Bank Ag | 2023-12-31 | 1.3 M | |
| Jpmorgan Chase & Co | 2023-12-31 | 1.2 M | |
| Alphacentric Advisors, Llc | 2023-12-31 | 1.1 M | |
| Tejara Capital Ltd | 2023-12-31 | 1 M | |
| Blackrock Inc | 2023-12-31 | 10.1 M | |
| Vanguard Group Inc | 2023-12-31 | 8.7 M |
Karyopharm Therapeutics Historical Income Statement
Karyopharm Therapeutics Income Statement is one of the three primary financial statements used for reporting Karyopharm's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Karyopharm Therapeutics revenue and expense. Karyopharm Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Karyopharm Therapeutics' Income Tax Expense is increasing as compared to previous years. The Karyopharm Therapeutics' current Interest Income is estimated to increase to about 10.2 M, while Depreciation And Amortization is projected to decrease to under 503.5 K. View More FundamentalsKaryopharm Stock Against Markets
Picking the right benchmark for Karyopharm Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Karyopharm Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Karyopharm Therapeutics is critical whether you are bullish or bearish towards Karyopharm Therapeutics at a given time. Please also check how Karyopharm Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Karyopharm Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
Karyopharm Therapeutics Corporate Directors
Karyopharm Therapeutics corporate directors refer to members of a Karyopharm Therapeutics board of directors. The board of directors generally takes responsibility for the Karyopharm Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Karyopharm Therapeutics' board members must vote for the resolution. The Karyopharm Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Deepa Pakianathan | Director | Profile | |
| Kenneth Weg | Director | Profile | |
| Deepika Pakianathan | Independent Director | Profile | |
| Mikael Dolsten | Director | Profile |
How to buy Karyopharm Stock?
Before investing in Karyopharm Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Karyopharm Therapeutics. To buy Karyopharm Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Karyopharm Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Karyopharm Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Karyopharm Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Karyopharm Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Karyopharm Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
Already Invested in Karyopharm Therapeutics?
The danger of trading Karyopharm Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Karyopharm Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Karyopharm Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Karyopharm Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Karyopharm Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.25) | Revenue Per Share 1.279 | Quarterly Revenue Growth 0.005 | Return On Assets (0.27) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.